AchieveCE Antibiotic Treatment for Complicated UTI
This course discusses the different FDA-approved antibiotics for the treatment of complicated urinary tract infections (UTIs). It talks about the pharmacology, clinical studies, adverse effects, dosage, and administration of Meropenem/Vaborbactam (Vabomere), Plazomicin (Zemdri), and Cefiderocol (Fetroja) for proper use.
-Desktop, Mobile, and Tablet friendly.
-No Time Limits or Expiration
-Includes an evaluation and assessment
-Credits are reported to CE Broker automatically within 24 hours
Meropenem/Vaborbactam (Vabomere) for Complicated Urinary Tract Infection
Plazomicin (Zemdri) – A New Aminoglycoside Antibiotic
Cefiderocol (Fetroja) – A New IV Cephalosporin for Complicated UTI
Upon completion of this activity, the participant will be able to:
1. Review the efficacy and safety of Meropenem/Vaborbactam (Vabomere), Plazomicin (Zemdri), and IV cefiderocol (Fetroja), for treatment of complicated urinary tract infections caused by susceptible gram-negative bacteria.
2. Discuss the pharmacologic options available for treatment of complicated UTI and compare them based on their efficacy, dosage and administration, and potential adverse effects.
3. Determine the most appropriate antibiotic given the clinical presentation of an individual patient with complicated UTI.
Physician, Physician Assistant, Podiatrist
Additional credit info
This CME activity was planned and produced in accordance with the ACCME Essentials and Policies through the joint providership of The Medical Letter and AchieveCE. The Medical Letter is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The Medical Letter ® designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.